Prepn: A. J. Ewins, GB 507565 (1939); J. N. Ashley et al., J. Chem. Soc. 1942, 103; of isethionate: G. Newbery, A. P. T. Easson, US 2394003 (1946 to May & Baker). Trypanocidal activity: E. M. Lourie, W. Yorke, Ann. Trop. Med. Parasitol. 33, 289 (1939). Preliminary pharmacological studies in animals: R. Wien, ibid. 37, 1 (1943). Activity in fibrinolytic systems: J. D. Geratz, Thromb. Diath. Haemorrh. 29, 154 (1973). Pharmacodynamics in men and mice: T. P. Waalkes et al., Clin. Pharmacol. Ther. 11, 505 (1970). In vitro activity against Pneumocystis carinii: E. L. Pesanti, C. Cox, Infect. Immun. 34, 908 (1981). Uptake and distribution of aerosolized form in animals: R. J. Debs et al., Am. Rev. Respir. Dis. 135, 731 (1987). In vivo efficacy of aerosolized form in rats: eidem, Antimicrob. Agents Chemother. 31, 37 (1987). Determn in plasma, urine and tissues: T. P. Waalkes, V. T. DeVita, J. Lab. Clin. Med. 75, 871 (1970); by HPLC: C. M. Dickinson et al., J. Chromatogr. 345, 91 (1985). Preliminary clinical evaluation in P. carinii pneumonia: V. T. DeVita et al., N. Engl. J. Med. 280, 287 (1968). Comparison with sulfamethoxazole-trimethoprim mixture in P. carinii pneumonia in AIDS: J. M. Wharton et al., Ann. Intern. Med. 105, 37 (1986). Early review of pharmacology, mode of action and clinical applications: E. B. Schoenbach, E. M. Greenspan, Medicine 27, 327-377 (1948). Review: S. Drake et al., Clin. Pharm. 4, 507-516 (1985); M. Sands et al., Rev. Infect. Dis. 7, 625-634 (1985); of activity, pharmacokinetics and therapeutic use: K. L. Goa, D. M. Campoli-Richards, Drugs 33, 242-258 (1987).
Antiprotozoal (Trypanosoma, Leishmania); antipneumocystic.
Antipneumocystic; Antiprotozoal (Leishmania); Antiprotozoal (Trypanosoma)